ArticleScientific reports2025
Genetic analyses reveal association between rosacea and cardiovascular diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence-enabled precision medicine for inflammatory skin diseases.The Journal of investigative dermatology · 2026Review
- Neuro-immune-vascular interactions in rosacea and hypertension: a mechanistic review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown that patients with rosacea tend to have a higher risk of developing cardiovascular diseases (CVDs). However, the potential causal relationship between genetic susceptibility to rosacea and the risk of CVDs remains unclear. Based on summary statistics from publicly available genome-wide association studies (GWASs), we detected the genetic association between rosacea and CVDs by a bidirectional two-sample Mendelian randomization (MR) analysis. The inverse-variance weighted (IVW) method was used as the primary analysis, while weighted median (WM) and MR-Egger were applied as complementary methods. For sensitivity analyses, we applied Cochran's Q test, the intercept of MR-Egger, MR-Pleiotropy Residual Sum and Outlier (MR-PRESSO), funnel plot, and leave-one-out analysis. The MR analysis revealed that rosacea was associated with an elevated risk of hypertension (HTN) (OR = 1.0032, 95% CI [1.0001-1.0063], P = 0.04). However, no casual relationship was found between rosacea and risk of atrial fibrillation (AF) (OR = 1.0099, 95% CI [0.9823-1.0382], P = 0.49), coronary artery disease (CAD) (OR = 1.0138, 95% CI [0.9824-1.0462], P = 0.39), heart failure (HF) (OR = 0.9965, 95% CI [0.9671-1.0268], P = 0.82), ischemic stroke (IS) (OR = 0.9933, 95% CI [0.9545-1.0337], P = 0.74), or myocardial infarction (MI) (OR = 1.0001, 95% CI [0.9988-1.0013], P = 0.92). In the sensitivity analysis, significant heterogeneity was revealed in the MI subgroup according to the Cochran's Q test. Other sensitivity analyses indicated the stability of our results. Reverse MR analysis showed no significant genetic effect of cardiovascular disease on rosacea risk. We are the first to use MR analysis to explore the casual relationship between rosacea and the risk of various CVDs, revealing an increased risk of HTN in patients with rosacea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.